Ann: Botanix Expands Clinical Capabilities, page-3

Impressive appointments.
Ex SANOFI and NOVARTIS

​

Dr Levy brings significant experience having most recently been the Vice-President of Research and Development at global dermatology company Almirall’s US subsidiary Aqua Pharmaceuticals. Prior to that, Dr Levy was Vice President and Medical Unit Head of Immunology and Dermatology for Novartis in the US, and Vice President North America Medical Affairs for Sanofi. As part of these roles, Dr Levy has been responsible for clinical development and clinical medical affairs programs, which led to recent successful launches of prescription and cosmetic dermatology products.
Dr Levy said: "I am excited about joining the Company at this important time, as Botanix’s acne and atopic dermatitis programs progress into Phase 2 clinical trials. It is clear that patients and their health care providers still need new therapies to treat these skin diseases. The data already generated by Botanix with their unique products, provides great potential for success."
Ms Chapas-Reed also brings significant experience in both clinical trial management and dermatology and joins Botanix from Churchill Pharmaceuticals (Churchill) where she most recently led a Phase 2/3 study that was successfully approved by the FDA in May 2018. Prior to Churchill, Ms Chapas-Reed
worked with both pharmaceutical development and clinical trial services companies managing several clinical trials ranging from atopic dermatitis to pain.